Coronary Access After Supra-Annular THV Implantation

Launched by UNIVERSITY OF BRITISH COLUMBIA · Oct 7, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Coronary Access After Supra-Annular THV Implantation," is looking to find the best way to access the coronary arteries after a specific heart procedure called Transcatheter Aortic Valve Replacement (TAVR) using a device known as the Evolut THV. The goal is to figure out the most effective techniques and tools for doctors to use during and after this procedure, especially when aligning the device correctly.

To participate in this study, you must be between 65 and 74 years old and scheduled for an elective TAVR with the Evolut THV. It's important that you can provide written consent to join the study. However, if you have certain health conditions, like severe kidney disease or a history of specific heart surgeries, you may not be eligible. If you join, you can expect to undergo the TAVR procedure while researchers observe and record how well the coronary arteries can be accessed afterward. This research could help improve future heart procedures for patients like you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients undergoing elective transfemoral TAVR with the Evolut THV (Medtronic, Minneapolis, MN, USA).
• • 2. Written informed consent to participate in the study.
• Exclusion Criteria:
• • 1. Hemodynamic or respiratory instability immediately prior to TAVR or during TAVR.
• • 2. Advanced chronic kidney disease, defined as a GFR \<30 ml/min.
• • 3. Valve-in-valve TAVR
• • 4. Prior CABG
• • 5. Aorto-ostial coronary artery disease.
• • 6. Prior PCI of the left main or right coronary ostium